Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19